AbbVie is a research-based biopharma company, developing small molecules and biologics for the treatment of various diseases.
In 2013, Abbott Laboratories splits into two entities- Abbott, Inc., to market medical and diagnostic products and AbbVie, Inc. the research and development focused biopharma company.
- In July 2019, AbbVie acquired Mavupharma, a Seattle, WA-based biopharma company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer, for an undisclosed amount. The acquisition will allow AbbVie to enhance its early stage oncology pipeline.
- In Mar 2015, AbbVie acquired Pharmacyclics in approx. $21 billion USD. Pharmacyclics was having Imbruvica® (ibrutinib) a Bruton’s tyrosine kinase (BTK) inhibitor approved for use in four indications to treat three different types of blood cancers including chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom’s macroglobulinemia.
- In Jan 2014, AbbVie acquired ImmuVen for an undisclosed amount. ImmuVen develops drugs to treat infectious diseases, cancer, and autoimmune disorders.
- In Mar 2010, Abbott acquire and merge Facet Biotech (in approx $450 Mn) to boost its early- and mid-stage cancer research pipeline. Originally, Facet was a subsidiary of PDL BioPharma but on Dec 2008 after capitalizing Facet with $405 Mn, PDL spun-off its subsidiary. At the time of acquisition, Facet’s pipeline includes Volociximab (PH II), Elotuzumab (PH I) and PDL192 (PH I) for cancer.
Page 1 of 3
